Quantum-Si incorporated (QSI)
| Market Cap | 186.14M -42.4% |
| Revenue (ttm) | 1.85M -46.2% |
| Net Income | -103.82M |
| EPS | -0.50 |
| Shares Out | 217.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,909,693 |
| Open | 0.8377 |
| Previous Close | 0.8573 |
| Day's Range | 0.7951 - 0.8898 |
| 52-Week Range | 0.6912 - 3.1000 |
| Beta | 3.17 |
| Analysts | Buy |
| Price Target | 2.50 (+192.47%) |
| Earnings Date | Aug 4, 2026 |
About QSI
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer’s protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-... [Read more]
Financial Performance
In 2025, Quantum-Si incorporated's revenue was $2.44 million, a decrease of -20.34% compared to the previous year's $3.06 million. Losses were -$101.34 million, 0.33% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for QSI stock is "Buy." The 12-month stock price target is $2.5, which is an increase of 192.47% from the latest price.
News
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Quantum-Si announces partnership with Cell Signaling Technology
Quantum-Si (QSI) announced a partnership with Cell Signaling Technology to advance and validate next-generation protein sequencing and analysis of post-translational modifications on the Proteu single...
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™.
Quantum-Si announces expansion of Proteus Roadshow
Quantum-Si (QSI) announced the expansion of a roadshow designed to accelerate the education of the market on its Proteus platform and applications for protein sequencing. The roadshow includes informa...
Quantum-Si Announces the Expansion of the Proteus™ Roadshow
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow.
Quantum-Si incorporated Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Proteus, a next-generation protein sequencing platform, is set for late 2024 launch with a scalable roadmap, enhanced PTM detection, and a $425,000 price point. Ongoing upgrades will be delivered via software and consumables, supported by strong cash reserves and a global commercialization strategy.
Quantum-Si incorporated Earnings Call Transcript: Q1 2026
Q1 2026 saw modest revenue and disciplined spending as focus shifted to the Proteus platform, which achieved key development milestones and strong early customer interest. Cash reserves remain robust, supporting operations into 2028, with commercial launch of Proteus on track for year-end.
Quantum-Si incorporated Earnings release: Q1 2026
Quantum-Si incorporated released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Quantum-Si incorporated Quarterly report: Q1 2026
Quantum-Si incorporated has published its Q1 2026 quarterly earnings report on May 7, 2026.
Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones.
Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.
Quantum-Si announces sequencing on Integrated Proteus instruments
Quantum-Si (QSI) Incorporated demonstrated sequencing on integrated Proteus instruments. The company said, “This milestone was achieved using a developmental sequencing kit, the KinetIQ Array, and ful...
Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments.
Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026.
Quantum-Si announces two customer posters to be presented at AACR meeting
Quantum-Si (QSI) announced that there will be two customer posters presented at the American Association of Cancer Research annual meeting on April 17-22, 2026 in San Diego, California. Poster Title:…
Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting.
Quantum-Si announces new manuscript on bioRxiv
Quantum-Si (QSI) Incorporated announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute. In the pr...
Quantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces New Manuscript Demonstrating Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies.
Quantum-Si announces customer samples tested on Proteus prototype system
Quantum-Si (QSI) has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Plati...
Quantum-Si announces customer samples tested on Proteus prototype system
Quantum-Si (QSI) has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Plati...
Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System.
Quantum-Si Announces the Start of the Proteus™ Roadshow
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Start of the Proteus™ Roadshow.
Quantum-Si incorporated Proxy statement: Proxy filing
Quantum-Si incorporated filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Quantum-Si incorporated Proxy statement: Proxy filing
Quantum-Si incorporated filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Quantum-Si price target lowered to $1 from $1.50 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Quantum-Si (QSI) to $1 from $1.50 and keeps a Hold rating on the shares. The firm said 4Q25 results below…